Articles From: Gala Global, Inc. Plans for New Products and Service From Hemp and Cannabis to Galena Biopharma to Report Third Quarter 2014 Financial Results on Monday, November 3, 2014


http://media.marketwire.com/attachments/201411/288786_logoGALAGlobal.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1156849&ProfileId=051205&sourceType=1 LOS ANGELES, CA --
Sign-up for Gala Global, Inc. Plans for New Products and Service From Hemp and Cannabis investment picks
LAS VEGAS, Aug.
Sign-up for Galaxy Gaming Enters Czech Republic investment picks
2014/9/26
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1147556&ProfileId=051205&sourceType=1 NEW ORLEANS, LA --
Sign-up for GALECTIN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT investment picks
NEW ORLEANS, July 31, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
Sign-up for GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. -- GALT investment picks
NORCROSS, Ga., July 30, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced yesterday results of cohort 2 of its phase 1 clinical trial in patients with NASH with advanced fibrosis.
Sign-up for Galectin Therapeutics Issues Statement on GR-MD-02 Development Program investment picks
NORCROSS, Ga., Aug.
Sign-up for Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter investment picks
NORCROSS, Ga., Aug.
Sign-up for Galectin Therapeutics Reports Second Quarter 2014 Financial Results investment picks
NORCROSS, Ga., Aug.
Sign-up for Galectin Therapeutics Responds to Class Action Lawsuit investment picks
NORCROSS, Ga., July 25, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced the Company will hold a webcast on Tuesday, July 29, 2014 at 8:30 a.m. Eastern Daylight Time to discuss the findings from cohort 2 of a Phase 1 clinical trial evaluating its galectin inhibitor GR-MD-02 in fatty liver disease (NASH) with advanced fibrosis.
Sign-up for Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis investment picks
Preliminary data shows a 31% recurrence rate in the vaccine group compared to 50% in the control group at a median follow up of 13 months, a 38% reduction in relative risk of recurrence GALE-301 plus GM-CSF is well tolerated and elicits a strong in vivo immune response with primarily Grade 1 and Grade 2 toxicities Top-line data to be presented mid-year 2015 PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase 2a Clinical Trial Data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting investment picks
- Allowed claims will cover the use of NeuVax alone or in combination to prevent recurrence of any breast cancer tumor expressing low-to-intermediate levels of HER2 - Extends patent coverage to three main markets, U.S., EU and now Japan PORTLAND, Ore., Oct.
Sign-up for Galena Biopharma Receives Notice of Allowance of Improvement Patent for NeuVax(TM) (nelipepimut-S) in Japan investment picks
2014/8/11
Abstral® (fentanyl) sublingual tablet net revenue was $2.3 million in Q2 2014 and $4.5 million in 1H 2014.
Sign-up for Galena Biopharma Reports Second Quarter 2014 Results investment picks
Clinical programs advance on multiple fronts, with trial initiation, trial enrollment, data and IP milestones achieved and anticipated Commercial strategy reinforced with product acquisition and upcoming commercial launch Abstral ® (fentanyl) sublingual tablet net revenue was $1.6 million in Q3 2014 and $6.1 million to date this year, with reiterated guidance of $8-$10 million for the full year 2014 Zuplenz ® (ondansetron) Oral Soluble Film U.S. rights licensed; launch expected in Q1 2015 Conference call scheduled for 5:00 pm E.T. today with details below PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma Reports Third Quarter 2014 Results investment picks
PORTLAND, Ore., Sept.
Sign-up for Galena Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference investment picks
PORTLAND, Ore., July 29, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE) , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that the Company will report its second quarter financial results on Monday, August 11, 2014 after the close of the financial markets.
Sign-up for Galena Biopharma to Report Second Quarter 2014 Financial Results on Monday, August 11, 2014 investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Gala Global, Inc. Plans for New Products and Service From Hemp and Cannabis to Galena Biopharma to Report Third Quarter 2014 Financial Results on Monday, November 3, 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent